Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/84—Nitriles
  • C07D213/85—Nitriles in position 3

Definitions

• This invention relates to novel 3-amino-4-phenyl-1H-pyrazolo[3,4-b]pyridines and non-toxic acid addition salts thereof, as well as to a method of preparing these compounds.
• the present invention relates to a novel class of 1H-pyrazolo[3,4-b]pyridines represented by the formula ##STR2## wherein
• R 1 is mono- or di-substituted amino, where the substituents are selected from the group consisting of alkyl of 1 to 6 carbon atoms, cyclohexyl, allyl and benzyl; unsubstituted, mono-substituted or di-substituted pyrrolidino, piperidino, hexamethyleneimino, morpholino, piperazino, thiomorpholino, 1-oxido-thiomorpholino or 1,1-dioxido-thiomorpholino, where the substituents are selected from the group consisting of methyl, hydroxymethyl, hydroxyl, phenyl and benzyl; 1,2,5,6-tetrahydropyridino; 1,2,3,4-tetrahydroisoquinolino; indolino; or 3,6-ethylene-hexamethyleneimino;
• R 2 is hydrogen, methyl or benzyl
• R 3 is hydrogen, halogen, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms;
• variable substitutes R 1 , R 2 and R 3 are the following:
• R 1 Metallamino, ethylamino, propylamino, isopropylamino, butylamino, isoamylamino, hexylamino, benzylamino, dimethylamino, diethylamino, dipropylamino, dibutylamino, diisobutylamino, dipentylamino, N-methyl-N-ethyl-amino, N-methyl-N-propyl-amino, N-methyl-N-hexyl-amino, N-ethyl-N-propyl-amino, N-ethyl-N-butyl-amino, N-ethyl-N-pentyl-amino, N-propyl-N-butyl-amino, N-butyl-N-pentyl-amino, diallylamino, N-methyl-N-cyclohexyl-amino,
• R 2 Hydrogen, methyl or benzyl
• R 3 Hydrogen, fluorine, chlorine, bromine, methyl, ethyl, propyl, methoxy, ethoxy or isopropoxy.
• R 1 is ethylamino, isopropylamino, isoamylamino, benzylamino, dimethylamino, diethylamino, dipropylamino, dibutylamino, diisobutylamino, N-methyl-N-cyclohexyl-amino, N-methyl-N-benzyl-amino, diallylamino, pyrrolidino, hexamethyleneimino, piperidino, methyl-piperidino, hydroxymethyl-piperidino, hydroxy-piperidino, phenyl-piperidino, benzyl-piperidino, dimethyl-piperidino, morpholino, methyl-morpholino, dimethyl-morpholino, piperazino, N-methyl-piperazino, N-phenyl-piperazino, N-benzyl-piperazino, thiomorpholino, dimethyl-thiomorpholino, 1-oxid
• R 2 is hydrogen, methyl or benzyl
• R 3 is hydrogen, fluorine, chlorine, methyl or methoxy; and non-toxic, pharmacologically acceptable acid addition salts thereof.
• R 1 is diethylamino, pyrrolidino, piperidino, 3-methyl-piperidino, hexamethyleneimino, morpholino or thiomorpholino;
• R 2 is hydrogen
• R 3 is hydrogen, fluorine, chlorine, methyl or methoxy
• R 3 has the same meanings as in formula I;
• R 1 ' has the meanings defined for R 1 in formula I or N'-acyl-piperazino
• X is a nucleaphilically exchangeable, so-called leaving group, for example chlorine, bromine or aryloxy, such as phenoxy; with a hydrazine of the formula ##STR4## wherein R 2 has the same meanings as in formula I.
• the reaction is advantageously carried out in the presence of a solvent such as dimethyl formamide, dimethyl sulfoxide, water, ethylene glycol, propylene glycol, 2-ethoxy-ethanol or in a stoichiometric excess of the hydrazine reactant of the formula III, optionally in the presence of a base such as sodium carbonate, pyridine or a sufficient excess of the hydrazine reactant, and at elevated temperatures, for instance at temperatures between 70° and 180° C., but preferably at temperatures between 100° and 150° C.
• a solvent such as dimethyl formamide, dimethyl sulfoxide, water, ethylene glycol, propylene glycol, 2-ethoxy-ethanol or in a stoichiometric excess of the hydrazine reactant of the formula III
• a base such as sodium carbonate, pyridine or a sufficient excess of the hydrazine reactant
• the starting compounds of the formula II are also new, but may be prepared by known methods, for instance by reacting a corresponding 2,6-dihalo-3-cyano-4-phenyl-pyridine with an amine of the formula
• R 1 ' has the same meanings as in formula II, in the presence of a solvent and at elevated temperatures, for example at the boiling point of a particular solvent which is used.
• the compounds embraced by formula I are organic bases and therefore form acid addition salts with inorganic or organic acids.
• Examples of non-toxic, pharmacologically acceptable acid addition salts are those formed with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, lactic acid, citric acid, tartaric acid, maleic acid, fumaric acid, 8-chlorotheophylline or the like.
• the raw product was dissolved in chloroform (the small amount of insoluble matter was filtered off) and purified by passing the solution through a short silicagel column with chloroform as the flow agent.
• the combined chloroform fractions were evaporated, leaving as a residue 37.5 gm (75% of theory) of virtually colorless crystalline 2,6-dichloro-4-phenyl-3-cyano-pyridine of the formula ##STR5## which had a melting point of 167°-169° C.
• 6-Ethylamino-3-amino-4-phenyl-1H-pyrazolo[3,4-b]pyridine m.p. 208°-210° C.
• 6-ethylamino-2-chloro-4-phenyl-3-cyano-pyridine m.p. 215°-218° C.
• hydrazine hydrate 6-ethylamino-2-chloro-4-phenyl-3-cyano-pyridine
• 3-Amino-6-(2,6-dimethyl-morpholino)-4-phenyl-1H-pyrazolo[3,4-b]-pyridine was prepared analogous to Example 1 from 2-chloro-6-(2,6-dimethyl-morpholino)-4-phenyl-3-cyano-pyridine (m.p. 165°-178° C.; mixture of isomers) and hydrazine hydrate. M.p. of the hydrochloride: 235°-238° C. (decomp.).
• 3-Amino-4-phenyl-6-piperazino-1H-pyrazolo[3,4-b]pyridine was prepared analogous to Example 1 from 2-chloro-6-(N'-formyl-piperazino)-4-phenyl-3-cyano-pyridine (m.p. 180°-182° C.) and hydrazine hydrate at 150° C. M.p. of the dihydrochloride: 263°-265° C. (from absolute ethanolic hydrochloric acid).
• 6-(3,6-Ethylene-hexamethyleneimino)-3-amino-4-phenyl-1H-pyrazolo[3,4-b]pyridine m.p. 241°-243° C.
• 6-(3,6-ethylene-hexamethyleneimino)-2-chloro-4-phenyl-3-cyano-pyridine m.p. 136°-138° C.
• hydrazine hydrate 6-(3,6-Ethylene-hexamethyleneimino)-3-amino-4-phenyl-1H-pyrazolo[3,4-b]pyridine
• the compounds of the present invention that is, those embraced by formula I above and their non-toxic, pharmacologically acceptable acid addition salts, have useful pharmacodynamic properties. More particularly, they exhibit antithrombotic and antiphlogistic activities in warm-blooded animals such as mice.
• the thrombocyte aggregation was measured in the platelet-rich plasma of healthy human donors.
• the course of change of the optical density of the platelet suspension was measured and recorded photometrically after the addition of commercial collagen containing 1 mg of collagen fibrils per ml. From the angle of inclination of the density curve, the rate of aggregation was estimated (Vmax).
• the optical density (O.D.) was taken as the point on the curve where the most light was transmitted.
• test compounds were incubated at 37° C. for 10 minutes with the plasma before aggregation was provoked.
• the compounds were dissolved with a small quantity of hydrochloric acid or dimethyl formamide, and the solution was diluted to the desired final concentration with distilled water.
• the acute toxicity of the compounds was determined in white mice (observation time: 14 days) after oral application of a single dose:
• the compounds of the present invention are useful for the prophylactic acid therapeutic treatment of arterial thromboembolisms and arterial occlusion disorders.
• the compounds of the present invention are administered to warm-blooded animals perorally, parenterally or rectally as active ingredients in customary dosage unit compositions, that is, compositions in dosage unit form consisting essentially of an inert pharmaceutical carrier and one effective dosage unit of the active ingredient, such as tablets, coated pills, capsules, wafers, powders, solutions, suspensions, emulsions, syrups, suppositories and the like.
• One effective dosage unit of the compounds according to the present invention is from 0.83 to 3.34 mgm/kg body weight, preferably from 2.0 to 2.84 mgm/kg body weight.
• the tablet composition is compounded from the following ingredients:
• the active ingredient is intimately admixed with the lactose and the potato starch, the mixture is uniformly moistened with an ethanolic 20% solution of the polyvinylpyrrolidone, and the moist mass is granulated through a 2.0 mm-mesh screen.
• the granulate is dried at 45° C., passed through a 1.5 mm-mesh screen and admixed with the magnesium stearate, and the composition is compressed into 470 mgm-tablets in a conventional tablet press.
• Each tablet is an oral dosage unit composition containing 150 mgm of the active ingredient.
• the pill core composition is compounded from the following ingredients:
• the ingredients are compounded in the same manner as in the preceding example, and the composition is compressed into 320 mgm-pill cores which are subsequently coated with a thin shell consisting essentially of a mixture of sugar and talcum and finally polished with beeswax.
• Each coated pill is an oral dosage unit composition containing 100 mgm of the active ingredient.
• the solution is compounded from the following ingredients:
• Distilled water is pretreated by boiling it and then cooling it to room temperature in an atmosphere of nitrogen.
• the polyethylene glycol and the active ingredient are then dissolved in the pretreated distilled water in an atmosphere of nitrogen, and the solution is diluted to the indicated volume with additional pretreated distilled water and then filtered until free from suspended particles.
• the filtrate is filled into brown 5cc-ampules in an atmosphere of nitrogen, which are then sterilized for 20 minutes at 121° C. and sealed. The entire procedure must be carried out in diffused light.
• the contents of each ampule are an injectable dosage unit composition containing 100 mgm of the active ingredient.
• the solution is compounded from the following ingredients:
• the sorbic acid is dissolved in the ethanol, an equal volume of distilled water is added thereto, and the active ingredient is dissolved in the solution (solution I).
• the sugar is dissolved in the remaining distilled water (solution II).
• Solution II, the polyethylene glycol and the essence of cacao are added to solution I while stirring, and the resulting solution is filtered.
• 1 ml of the filtrate (about 20 drops) is an oral dosage unit composition containing 50 mgm of the active ingredient.
• the suppository composition is compounded from the following ingredients:
• the finely pulverized active ingredient is homogeneously blended with an immersion homogenizer into the suppository base which had previously been melted and cooled to 40° C. 1700 mgm-portions of the mixture are poured at 38° C. into cooled suppository molds and allowed to harden therein.
• Each suppository is a rectal dosage unit composition containing 200 mgm of the active ingredient.
• any one of the other compounds embraced by formula I or a non-toxic pharmacologically acceptable acid addition salt thereof may be substituted for the particular active ingredient in Examples 50 through 54.
• the amount of active ingredient in these illustrative examples may be varied to achieve the dosage unit range set forth above, and the amounts and nature of the inert pharmaceutical carrier ingredients may be varied to meet particular requirements.

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=5989097

Family Applications (3)

Family Applications After (2)

Country Status (21)

Cited By (4)

Families Citing this family (12)

Citations (2)

Family Cites Families (1)

• 1976
  • 1976-09-29 DE DE19762643753 patent/DE2643753A1/de not_active Withdrawn
• 1977
  • 1977-09-07 FI FI772655A patent/FI61899C/fi not_active IP Right Cessation
  • 1977-09-19 US US05/834,114 patent/US4182887A/en not_active Expired - Lifetime
  • 1977-09-19 AT AT670077A patent/AT359064B/de not_active IP Right Cessation
  • 1977-09-22 AU AU29037/77A patent/AU513406B2/en not_active Expired
  • 1977-09-26 IL IL52997A patent/IL52997A/xx unknown
  • 1977-09-26 LU LU78179A patent/LU78179A1/xx unknown
  • 1977-09-27 GR GR54440A patent/GR64049B/el unknown
  • 1977-09-28 SE SE7710873A patent/SE7710873L/xx not_active Application Discontinuation
  • 1977-09-28 IE IE1988/77A patent/IE45700B1/en unknown
  • 1977-09-28 NZ NZ185292A patent/NZ185292A/xx unknown
  • 1977-09-28 PT PT67091A patent/PT67091B/pt unknown
  • 1977-09-28 JP JP11657277A patent/JPS5344588A/ja active Pending
  • 1977-09-28 ZA ZA00775784A patent/ZA775784B/xx unknown
  • 1977-09-28 GB GB40364/77A patent/GB1552730A/en not_active Expired
  • 1977-09-28 BE BE181275A patent/BE859152A/xx unknown
  • 1977-09-28 NO NO773327A patent/NO147913C/no unknown
  • 1977-09-28 NL NL7710573A patent/NL7710573A/xx not_active Application Discontinuation
  • 1977-09-28 DK DK428477A patent/DK143183C/da active
  • 1977-09-28 ES ES462700A patent/ES462700A1/es not_active Expired
  • 1977-09-29 FR FR7729322A patent/FR2366290A1/fr active Granted
• 1979
  • 1979-09-13 US US06/075,493 patent/US4224322A/en not_active Expired - Lifetime
  • 1979-09-13 US US06/075,100 patent/US4260621A/en not_active Expired - Lifetime

Patent Citations (2)

Also Published As

Similar Documents